Q2 Earnings Forecast for Alto Neuroscience Issued By Wedbush

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Equities research analysts at Wedbush upped their Q2 2025 EPS estimates for shares of Alto Neuroscience in a research report issued on Thursday, May 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.68) per share for the quarter, up from their prior estimate of ($0.70). Wedbush has a "Neutral" rating and a $4.00 price objective on the stock. The consensus estimate for Alto Neuroscience's current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience's Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, FY2026 earnings at ($2.23) EPS and FY2029 earnings at ($2.87) EPS.

Other analysts also recently issued reports about the stock. HC Wainwright began coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a "buy" rating and a $10.00 price target on the stock. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Price Performance

NYSE ANRO traded up $0.12 on Monday, reaching $3.05. The company had a trading volume of 276,114 shares, compared to its average volume of 385,196. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $82.68 million, a PE ratio of -1.31 and a beta of 1.87. The firm's 50 day moving average price is $2.35 and its 200 day moving average price is $3.40. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. grew its stake in shares of Alto Neuroscience by 73.1% in the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock worth $7,158,000 after buying an additional 714,461 shares in the last quarter. Armistice Capital LLC grew its stake in shares of Alto Neuroscience by 146.2% in the 1st quarter. Armistice Capital LLC now owns 1,600,000 shares of the company's stock worth $3,456,000 after buying an additional 950,000 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Alto Neuroscience by 40.8% in the 4th quarter. Vestal Point Capital LP now owns 915,000 shares of the company's stock worth $3,870,000 after buying an additional 265,000 shares in the last quarter. AWM Investment Company Inc. grew its stake in shares of Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company's stock worth $1,948,000 after buying an additional 214,153 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Alto Neuroscience by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock worth $3,575,000 after purchasing an additional 36,319 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.